These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

557 related items for PubMed ID: 29567459

  • 1. 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC.
    Ojha R, Huang HL, HuangFu WC, Wu YW, Nepali K, Lai MJ, Su CJ, Sung TY, Chen YL, Pan SL, Liou JP.
    Eur J Med Chem; 2018 Apr 25; 150():667-677. PubMed ID: 29567459
    [Abstract] [Full Text] [Related]

  • 2. Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
    Ojha R, Nepali K, Chen CH, Chuang KH, Wu TY, Lin TE, Hsu KC, Chao MW, Lai MJ, Lin MH, Huang HL, Chang CD, Pan SL, Chen MC, Liou JP.
    Eur J Med Chem; 2020 Mar 15; 190():112086. PubMed ID: 32058238
    [Abstract] [Full Text] [Related]

  • 3. N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression.
    Mehndiratta S, Lin MH, Wu YW, Chen CH, Wu TY, Chuang KH, Chao MW, Chen YY, Pan SL, Chen MC, Liou JP.
    Eur J Med Chem; 2020 Jan 01; 185():111725. PubMed ID: 31655430
    [Abstract] [Full Text] [Related]

  • 4. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
    Jiang BE, Hu J, Liu H, Liu Z, Wen Y, Liu M, Zhang HK, Pang X, Yu LF.
    Eur J Med Chem; 2022 Jan 05; 227():113893. PubMed ID: 34656899
    [Abstract] [Full Text] [Related]

  • 5. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
    Chen J, Li D, Li W, Yin J, Zhang Y, Yuan Z, Gao C, Liu F, Jiang Y.
    Bioorg Med Chem; 2018 Aug 07; 26(14):3958-3966. PubMed ID: 29954683
    [Abstract] [Full Text] [Related]

  • 6. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
    Guan P, Sun F, Hou X, Wang F, Yi F, Xu W, Fang H.
    Bioorg Med Chem; 2012 Jun 15; 20(12):3865-72. PubMed ID: 22579621
    [Abstract] [Full Text] [Related]

  • 7. Discovery and preliminary evaluation of 2-aminobenzamide and hydroxamate derivatives containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors.
    Cai J, Wei H, Hong KH, Wu X, Cao M, Zong X, Li L, Sun C, Chen J, Ji M.
    Eur J Med Chem; 2015 Jun 15; 96():1-13. PubMed ID: 25874326
    [Abstract] [Full Text] [Related]

  • 8. Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity.
    Chetan B, Bunha M, Jagrat M, Sinha BN, Saiko P, Graser G, Szekeres T, Raman G, Rajendran P, Moorthy D, Basu A, Jayaprakash V.
    Bioorg Med Chem Lett; 2010 Jul 01; 20(13):3906-10. PubMed ID: 20605448
    [Abstract] [Full Text] [Related]

  • 9. Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
    Li X, Hou J, Li X, Jiang Y, Liu X, Mu W, Jin Y, Zhang Y, Xu W.
    Eur J Med Chem; 2015 Jan 07; 89():628-37. PubMed ID: 25462271
    [Abstract] [Full Text] [Related]

  • 10. Quinazolin-4(3H)-one-Based Hydroxamic Acids: Design, Synthesis and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
    Hieu DT, Anh DT, Hai PT, Thuan NT, Huong LT, Park EJ, Young Ji A, Soon Kang J, Phuong Dung PT, Han SB, Nam NH.
    Chem Biodivers; 2019 Apr 07; 16(4):e1800502. PubMed ID: 30653817
    [Abstract] [Full Text] [Related]

  • 11. Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
    Cincinelli R, Musso L, Giannini G, Zuco V, De Cesare M, Zunino F, Dallavalle S.
    Eur J Med Chem; 2014 May 22; 79():251-9. PubMed ID: 24742384
    [Abstract] [Full Text] [Related]

  • 12. Quinazoline-Based Hydroxamic Acids: Design, Synthesis, and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity.
    Hieu DT, Anh DT, Hai PT, Huong LT, Park EJ, Choi JE, Kang JS, Dung PTP, Han SB, Nam NH.
    Chem Biodivers; 2018 Jun 22; 15(6):e1800027. PubMed ID: 29667768
    [Abstract] [Full Text] [Related]

  • 13. Effect of C7-substitution of 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines on the selectivity towards a subclass of histone deacetylases.
    Lee HY, Wang LT, Li YH, Pan SL, Chen YL, Teng CM, Liou JP.
    Org Biomol Chem; 2014 Nov 28; 12(44):8966-76. PubMed ID: 25277250
    [Abstract] [Full Text] [Related]

  • 14. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT, Knoff JR, Pflum MKH.
    Eur J Med Chem; 2018 Jan 01; 143():1790-1806. PubMed ID: 29150330
    [Abstract] [Full Text] [Related]

  • 15. Synthesis and antitumor activity of novel diaryl ether hydroxamic acids derivatives as potential HDAC inhibitors.
    Zhu Y, Chen X, Wu Z, Zheng Y, Chen Y, Tang W, Lu T.
    Arch Pharm Res; 2012 Oct 01; 35(10):1723-32. PubMed ID: 23139122
    [Abstract] [Full Text] [Related]

  • 16. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
    Xie R, Yao Y, Tang P, Chen G, Liu X, Yun F, Cheng C, Wu X, Yuan Q.
    Eur J Med Chem; 2017 Jul 07; 134():1-12. PubMed ID: 28391133
    [Abstract] [Full Text] [Related]

  • 17. Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.
    Chao SW, Chen LC, Yu CC, Liu CY, Lin TE, Guh JH, Wang CY, Chen CY, Hsu KC, Huang WJ.
    Eur J Med Chem; 2018 Jan 01; 143():792-805. PubMed ID: 29223096
    [Abstract] [Full Text] [Related]

  • 18. Novel N-hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity.
    Huong TT, Dung DT, Huan NV, Cuong LV, Hai PT, Huong LT, Kim J, Kim YG, Han SB, Nam NH.
    Bioorg Chem; 2017 Apr 01; 71():160-169. PubMed ID: 28196602
    [Abstract] [Full Text] [Related]

  • 19. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
    Tazzari V, Cappelletti G, Casagrande M, Perrino E, Renzi L, Del Soldato P, Sparatore A.
    Bioorg Med Chem; 2010 Jun 15; 18(12):4187-94. PubMed ID: 20576572
    [Abstract] [Full Text] [Related]

  • 20. Design and synthesis of a new generation of substituted purine hydroxamate analogs as histone deacetylase inhibitors.
    Liu R, Wang J, Tang W, Fang H.
    Bioorg Med Chem; 2016 Apr 01; 24(7):1446-54. PubMed ID: 26907204
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.